Last reviewed: May 14, 2026
Last updated: May 14, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
GLP-1 medications do not directly cause osteoporosis, but some observational data suggests weight loss associated with these drugs may temporarily affect bone density. Recent studies indicate bone turnover markers may shift during early treatment, though long-term clinical implications remain under investigation.
For patients considering compounded GLP-1 options through PlexusDx, understanding your baseline bone health and genetic risk factors supports a more informed conversation with your provider. Precision wellness means evaluating not just medication efficacy, but how your individual metabolic profile and bone metabolism may respond.
How GLP-1 Medications May Affect Bone Metabolism
Weight loss from GLP-1 use may reduce mechanical loading on bones, potentially lowering bone mineral density (BMD) in short-term studies. This is not unique to GLP-1—rapid weight loss from any cause can temporarily increase bone turnover markers. The mechanism appears metabolic rather than direct drug toxicity.
Research shows bone resorption markers may increase during the first 6–12 months of GLP-1 therapy, while formation markers stabilize. However, bone loss rates in GLP-1 users are generally comparable to weight loss in non-GLP-1 populations, suggesting the medication itself is not the primary driver.
Key Bone Health Markers and GLP-1 Treatment Context
Before starting GLP-1 therapy, baseline assessment of bone turnover markers and BMD provides essential context for monitoring. Key markers include P1NP (bone formation), CTX (bone resorption), and DEXA scan results. These help your provider establish a personalized monitoring plan aligned with your bone health risk.
| Marker or Factor |
What It Tells You |
| P1NP (bone formation marker) |
Elevated levels indicate active bone-building; declining levels may suggest reduced formation during weight loss |
| CTX (bone resorption marker) |
Rising CTX in early GLP-1 use may reflect increased bone turnover; stabilization is expected over time |
| DEXA scan (BMD measurement) |
Baseline and follow-up scans help distinguish normal weight-loss effects from pathologic bone loss |
| Serum calcium and vitamin D |
Deficiencies compound bone health risk; correction before GLP-1 initiation is prudent |
Genetic Factors and Individual Bone Health Predispositions
Genetic variations in bone metabolism genes (e.g., VDR, RANKL, COLIA1) may influence how quickly bone density changes during weight loss. PlexusDx's Precision Peptide Genetic Test reveals predispositions in peptide metabolism pathways—understanding your baseline metabolic profile may provide context for bone health risk conversations with your provider.
Having genetic markers associated with lower baseline bone density or faster bone turnover does not predict exact GLP-1 outcomes, but can support a more personalized monitoring strategy. Patients with such predispositions may benefit from earlier baseline bone assessment and more frequent follow-up imaging.
Clinical Monitoring and Safety Considerations Before Starting GLP-1
Before initiating compounded semaglutide, tirzepatide, or other GLP-1 therapies from PlexusDx, a qualified healthcare provider should assess your bone health history, current vitamin D and calcium status, and any family history of osteoporosis. Baseline BMD and bone turnover markers establish a reference point for safe monitoring.
During GLP-1 treatment, periodic bone marker assessment and consideration of repeat DEXA imaging (typically annually for high-risk patients) helps your provider distinguish expected weight-loss effects from concerning bone loss. Adequate calcium and vitamin D intake, weight-bearing exercise, and smoking cessation remain foundational regardless of GLP-1 use.
How PlexusDx Supports a More Personalized Approach
PlexusDx's Precision Peptide Genetic Test may help provide context about your genetic predispositions in bone metabolism and metabolic regulation. Understanding variants related to bone turnover or calcium homeostasis can support a more targeted conversation with your provider about baseline bone assessment and monitoring frequency during GLP-1 therapy.
The Precision Peptide Genetic Test reveals predispositions in peptide genetic pathways—not exact medication response. Having genetic markers associated with altered bone turnover does not predict whether you will experience bone loss on GLP-1, but can inform your provider's decision to establish earlier baseline imaging or more frequent follow-up.
Combining genetic predisposition data with biomarker assessment (bone turnover markers and BMD baseline) and clinical history creates a more complete picture for your provider. This precision approach to GLP-1 selection and monitoring can help ensure bone health considerations are actively managed throughout your treatment journey.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Will GLP-1 medications cause me to develop osteoporosis?
No—GLP-1 does not directly cause osteoporosis. Weight loss associated with these drugs may temporarily affect bone turnover, but mechanisms are similar to weight loss from other causes. Individual risk depends on baseline bone health, genetics, and lifestyle factors.
What does the research actually show about GLP-1 and bone loss?
Observational studies show bone resorption markers may increase in early GLP-1 therapy, though bone loss rates are comparable to non-GLP-1 weight loss. Long-term fracture risk data remain limited, warranting ongoing research and provider monitoring.
How does PlexusDx's Precision Peptide Genetic Test help with bone health concerns?
The test reveals predispositions in peptide metabolic pathways, which may provide context for your bone turnover risk profile. Results should be interpreted with your provider to inform baseline bone assessment and personalized monitoring during GLP-1 therapy.
What should I do before starting compounded semaglutide or tirzepatide from PlexusDx?
Work with your provider to assess baseline bone health: vitamin D and calcium levels, BMD via DEXA if indicated, and bone turnover markers. This establishes a reference point for safe monitoring throughout your GLP-1 treatment.
Do people with a family history of osteoporosis need extra bone monitoring on GLP-1?
Yes. Family history and genetic predispositions suggest earlier baseline BMD assessment and potentially more frequent follow-up imaging. Ensure adequate calcium, vitamin D, weight-bearing exercise, and regular provider check-ins.
Related Reading
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
What Company Makes GLP-1 Drugs? A Deep Dive into the Innovators Behind These Weight Loss Solutions
How Deep to Inject Semaglutide for Optimal Results